These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 17768531)
1. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. Barros LF; Belfort R An Acad Bras Cienc; 2007 Sep; 79(3):389-94. PubMed ID: 17768531 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168 [TBL] [Abstract][Full Text] [Related]
4. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model. Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642 [TBL] [Abstract][Full Text] [Related]
5. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668 [TBL] [Abstract][Full Text] [Related]
6. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605 [TBL] [Abstract][Full Text] [Related]
7. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis. Tunik S; Nergiz Y; Keklikci U; Akkus M Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1161-7. PubMed ID: 22527313 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Kim TI; Kim SW; Kim S; Kim T; Kim EK Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123 [TBL] [Abstract][Full Text] [Related]
10. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093 [TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effects of Subconjunctival Injections of Bevacizumab and Interferon Alpha-2a on Corneal Angiogenesis in a Rat Model. Bilgin S Medicina (Kaunas); 2018 Apr; 54(2):. PubMed ID: 30344247 [TBL] [Abstract][Full Text] [Related]
14. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits. Yoo AR; Chung SK Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962 [TBL] [Abstract][Full Text] [Related]
15. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227 [TBL] [Abstract][Full Text] [Related]
16. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model. Avisar I; Weinberger D; Kremer I Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420 [TBL] [Abstract][Full Text] [Related]
17. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model. Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751 [TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Han YS; Lee JE; Jung JW; Lee JS Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]